<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451723</url>
  </required_header>
  <id_info>
    <org_study_id>K23AT004433-02</org_study_id>
    <secondary_id>K23AT004433-02</secondary_id>
    <secondary_id>K23AT004433</secondary_id>
    <nct_id>NCT01451723</nct_id>
  </id_info>
  <brief_title>Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II</brief_title>
  <acronym>POEMS</acronym>
  <official_title>Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisiana State University Health Sciences Center in New Orleans</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple&#xD;
      Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate&#xD;
      (a chemical that reflects the number of neurons and their metabolism) over one year between&#xD;
      people with MS treated with Polyphenon E at a dose of 400mg twice a day and people with MS&#xD;
      treated with a matching sugar pill.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double blind placebo controlled trial of Polyphenon E as a treatment for MS.&#xD;
&#xD;
      The primary outcome will be the changes in NAA levels over one year. Secondary outcomes will&#xD;
      be changes in brain atrophy over one year. As an exploratory outcome we will correlate&#xD;
      changes in NAA levels with free Plasma levels of EGCG 8 hours after the morning dose.&#xD;
&#xD;
      Exploratory outcomes include disability progression by EDSS, MS functional composite&#xD;
      components and a cognitive test battery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unusual high frequency of elevated liver function tests.&#xD;
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Change in NAA Levels Adjusted for Water Content.</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of change will be calculated using all the time points available )baseline, 6 and 12 months) using a mixed model analysis with the Log NAA as the dependent variable and water content, %grey matter, %white matter, %CSF and % lesion volume as covariates. All the voxels available for each subject where estimates have a SD &lt;30 will be used. A spatial anysotropic exponential covariance structure will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain Atrophy</measure>
    <time_frame>1 year</time_frame>
    <description>Difference between the two groups in brain atrophy as measured by SIENA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Polyphenon E 400mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyphenon E</intervention_name>
    <description>Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.</description>
    <arm_group_label>Polyphenon E 400mg twice a day</arm_group_label>
    <other_name>EGCG</other_name>
    <other_name>epigallocatechin gallate</other_name>
    <other_name>Green tea extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MS by McDonald criteria&#xD;
&#xD;
          -  Relapsing-remitting MS or secondary progressive MS&#xD;
&#xD;
          -  Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six&#xD;
             months&#xD;
&#xD;
          -  EDSS Score less than or equal to 7.0&#xD;
&#xD;
          -  Ages 18-60.&#xD;
&#xD;
          -  Participants must have normal organ and marrow function as defined below:&#xD;
&#xD;
               1. Leukocytes ≥3,000/µL&#xD;
&#xD;
               2. Absolute neutrophil count ≥1,500/µL&#xD;
&#xD;
               3. Platelets ≥100,000/µL&#xD;
&#xD;
               4. Total bilirubin ≤local upper limit of normal&#xD;
&#xD;
               5. AST (SGOT) ≤local upper limit of normal&#xD;
&#xD;
               6. ALT (SGPT) ≤local upper limit of normal&#xD;
&#xD;
               7. Creatinine ≤local upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MS relapse within the 30 days prior to enrollment&#xD;
&#xD;
          -  A primary progressive form of MS.&#xD;
&#xD;
          -  Previous treatment prior to study entry as follows: complete radiation ablation of the&#xD;
             bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone,&#xD;
             cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies&#xD;
             except the DMT's included in the inclusion criteria and methylprednisone for relapses&#xD;
             within prior nine months.&#xD;
&#xD;
          -  History of renal or liver disease.&#xD;
&#xD;
          -  Consumption of green tea or supplements containing green tea or tea extract within 30&#xD;
             days prior to enrollment.&#xD;
&#xD;
          -  Participants may not participate in any other clinical trial involving investigational&#xD;
             agents during the study, or within six months prior to enrolling in the study.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Polyphenon E, tea, or any of the inactive ingredients present in the&#xD;
             active or placebo capsules, including gelatin.&#xD;
&#xD;
          -  History of allergic reactions to gadolinium or any other condition contraindicated for&#xD;
             MRI.&#xD;
&#xD;
          -  Uncontrolled, clinically-relevant active illness (aside from MS) including, but not&#xD;
             limited to, ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
          -  Any condition which would make the subject, in the opinion of the investigator,&#xD;
             unsuitable for the study&#xD;
&#xD;
          -  Inability to complete the baseline MRI scan&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease,&#xD;
             gastritis, diverticulitis, colitis, hemorrhoids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus F Lovera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSUHSC-New Orleans</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LSu Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medschool.lsuhsc.edu/msclinic/</url>
    <description>LSU MS Clinic</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <results_first_submitted>December 10, 2013</results_first_submitted>
  <results_first_submitted_qc>January 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2014</results_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center in New Orleans</investigator_affiliation>
    <investigator_full_name>Jesus Lovera MD</investigator_full_name>
    <investigator_title>MD, MsPH</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Polyphenon E</keyword>
  <keyword>Green tea</keyword>
  <keyword>EGCG</keyword>
  <keyword>Epigallocatechin-galleate</keyword>
  <keyword>Placebo</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Polyphenon E 400mg Twice a Day</title>
          <description>Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.&#xD;
Polyphenon E: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo capsules.&#xD;
Placebo: Matching placebo capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study halted</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Polyphenon E 400mg Twice a Day</title>
          <description>Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.&#xD;
Polyphenon E: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo capsules.&#xD;
Placebo: Matching placebo capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="6.2"/>
                    <measurement group_id="B2" value="47" spread="7.6"/>
                    <measurement group_id="B3" value="48.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Change in NAA Levels Adjusted for Water Content.</title>
        <description>The rate of change will be calculated using all the time points available )baseline, 6 and 12 months) using a mixed model analysis with the Log NAA as the dependent variable and water content, %grey matter, %white matter, %CSF and % lesion volume as covariates. All the voxels available for each subject where estimates have a SD &lt;30 will be used. A spatial anysotropic exponential covariance structure will be used.</description>
        <time_frame>1 year</time_frame>
        <population>No subjects completed either the six or twelve month point so no data was available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Polyphenon E 400mg Twice a Day</title>
            <description>Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.&#xD;
Polyphenon E: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo capsules.&#xD;
Placebo: Matching placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in NAA Levels Adjusted for Water Content.</title>
          <description>The rate of change will be calculated using all the time points available )baseline, 6 and 12 months) using a mixed model analysis with the Log NAA as the dependent variable and water content, %grey matter, %white matter, %CSF and % lesion volume as covariates. All the voxels available for each subject where estimates have a SD &lt;30 will be used. A spatial anysotropic exponential covariance structure will be used.</description>
          <population>No subjects completed either the six or twelve month point so no data was available for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Atrophy</title>
        <description>Difference between the two groups in brain atrophy as measured by SIENA</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Polyphenon E 400mg Twice a Day</title>
            <description>Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.&#xD;
Polyphenon E: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo capsules.&#xD;
Placebo: Matching placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Atrophy</title>
          <description>Difference between the two groups in brain atrophy as measured by SIENA</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Polyphenon E 400mg Twice a Day</title>
          <description>Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.&#xD;
Polyphenon E: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo capsules.&#xD;
Placebo: Matching placebo capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated liver enzymes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was halted prematurely because of the high incidence of liver function abnormalities</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jesus Lovera MD</name_or_title>
      <organization>Louisiana Health Sciences Center-New Orleans</organization>
      <phone>50-903 9302</phone>
      <email>jlover@lsuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

